2 results
Approved WMORecruiting
Based on the scientific background and knowledge as detailed above this clinical proof-of-mechanism study is performed in order to determine if PET imaging with [18F]DPA-714 has the diagnostic potential to discriminate probable AD patients from…
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.